Revvity (NYSE:RVTY) Shares Gap Down to $109.86

Revvity, Inc. (NYSE:RVTYGet Free Report)’s share price gapped down before the market opened on Thursday . The stock had previously closed at $109.86, but opened at $107.31. Revvity shares last traded at $108.95, with a volume of 20,832 shares traded.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on RVTY shares. TD Cowen lifted their price objective on Revvity from $123.00 to $130.00 and gave the company a “buy” rating in a research report on Tuesday, April 30th. Jefferies Financial Group started coverage on Revvity in a research report on Monday, June 3rd. They issued a “hold” rating and a $115.00 price objective for the company. Finally, Robert W. Baird lifted their price objective on Revvity from $126.00 to $127.00 and gave the company an “outperform” rating in a research report on Tuesday, April 30th. Seven research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $117.92.

View Our Latest Research Report on RVTY

Revvity Price Performance

The company has a current ratio of 2.23, a quick ratio of 1.92 and a debt-to-equity ratio of 0.40. The company has a 50 day moving average price of $105.91 and a 200 day moving average price of $104.34. The company has a market capitalization of $13.69 billion, a price-to-earnings ratio of 91.67, a PEG ratio of 2.86 and a beta of 1.08.

Revvity (NYSE:RVTYGet Free Report) last announced its quarterly earnings data on Monday, April 29th. The company reported $0.98 EPS for the quarter, topping analysts’ consensus estimates of $0.94 by $0.04. Revvity had a return on equity of 7.37% and a net margin of 5.49%. The business had revenue of $649.90 million during the quarter, compared to analysts’ expectations of $646.83 million. During the same period in the previous year, the firm earned $1.01 earnings per share. The firm’s quarterly revenue was down 3.7% compared to the same quarter last year. As a group, equities research analysts forecast that Revvity, Inc. will post 4.65 earnings per share for the current year.

Revvity Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, August 9th. Investors of record on Friday, July 19th will be paid a dividend of $0.07 per share. The ex-dividend date is Friday, July 19th. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.25%. Revvity’s dividend payout ratio (DPR) is presently 23.14%.

Institutional Investors Weigh In On Revvity

A number of institutional investors have recently made changes to their positions in RVTY. Czech National Bank grew its stake in Revvity by 0.5% in the first quarter. Czech National Bank now owns 21,713 shares of the company’s stock valued at $2,280,000 after acquiring an additional 99 shares during the period. Gladius Capital Management LP grew its stake in Revvity by 84.1% in the third quarter. Gladius Capital Management LP now owns 232 shares of the company’s stock valued at $26,000 after acquiring an additional 106 shares during the period. Inspire Investing LLC grew its stake in Revvity by 2.9% in the first quarter. Inspire Investing LLC now owns 4,190 shares of the company’s stock valued at $440,000 after acquiring an additional 117 shares during the period. Tokio Marine Asset Management Co. Ltd. grew its stake in Revvity by 3.6% in the first quarter. Tokio Marine Asset Management Co. Ltd. now owns 3,899 shares of the company’s stock valued at $409,000 after acquiring an additional 135 shares during the period. Finally, Empirical Finance LLC grew its stake in Revvity by 3.7% in the first quarter. Empirical Finance LLC now owns 4,225 shares of the company’s stock valued at $444,000 after acquiring an additional 151 shares during the period. 86.65% of the stock is owned by institutional investors and hedge funds.

About Revvity

(Get Free Report)

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.

Featured Articles

Receive News & Ratings for Revvity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revvity and related companies with MarketBeat.com's FREE daily email newsletter.